NVDA
NVIDIA
-- 121.670 TSLA
Tesla
-- 249.980 QBTS
D-Wave Quantum
-- 10.150 PLTR
Palantir
-- 86.240 INTC
Intel
-- 24.050 
NEWS
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody -
- Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026 -
7 minutes ago, 4:00 AM PST
Via GlobeNewswire
CHRS
Share
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -
- Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody -
- Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026 -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment